drug · small molecule
avatrombopag maleate
Marketedupdated 3mo agoby Swedish Orphan Biovitrum AB🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for thrombocytopenia and liver disease.
targets
Thrombopoietin receptor
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 28, 2027
347 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 28, 2027compositionUS 7638536347d
- Jul 28, 2027compositionUS 7638536347d
FDA exclusivities (3)
- Jul 24, 2028I-974Indication (3y)1.9y
- Jul 24, 2028NPNP1.9y
- Jun 26, 2026ODE-246Orphan Drug (7y)
News(3)
- Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 pushSobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.fiercebiotech · 4d ago
- Chutes & Ladders—BioNTech brings in Sobi CEOAfter a six-month wait, BioNTech has finally filled its vacant CEO spot with Guido Oelkers, Ph.D. Oelkers hails from his tenure as CEO of Swedish pharma Sobi, where he oversaw the licensing of the…fiercebiotech · 8d ago
- After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA companyOne of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.fiercebiotech · 11d ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that